Icosabutate Market Size, Emerging Insight, and Forecast to 2032

This report provides comprehensive insights about Icosabutate for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Icosabutate for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the Icosabutate for NASH.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Icosabutate market forecast analysis for NASH in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary

The company’s Icosabutate, the lead product candidate of NorthSea Therapeutics BV, is a once-daily, oral SEFA currently in a Phase IIb clinical trial, referred to as the ICONA trial, for the treatment of NASH.

Fatty acids and their metabolites function as signaling molecules in a broad array of pathways in the liver regulating metabolic, inflammatory, and fibrotic responses. Icosabutate is an orally administered, structurally engineered, liver-targeted eicosapentaenoic acid derivative. The structural modifications result in high hepatic concentrations of non-esterified icosabutate that optimize the targeting of fatty acid receptors of key relevance to NASH, including FFAR4.

Preclinical data have demonstrated its therapeutic potential for treating fibrosing NASH and are of relevance to NASH patients; significant improvements in atherogenic lipids, glycemic control, and inflammation have been shown in clinical studies. The potential to target both NASH and its associated comorbidities, coupled with a favorable safety profile and oral administration, supports icosabutate as a potential novel treatment for a broad range of patients with NASH.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Icosabutate description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Icosabutate regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Icosabutate research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Icosabutate.
• The report contains forecasted sales of Icosabutate for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Icosabutate in NASH.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Icosabutate Analytical Perspective

In-depth Icosabutate Market Assessment

This report provides a detailed market assessment of Icosabutate for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

Icosabutate Clinical Assessment

The report provides the clinical trials information of Icosabutate for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Icosabutate dominance.
• Other emerging products for NASH are expected to give tough market competition to Icosabutate and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Icosabutate in NASH.
• This in-depth analysis of the forecasted sales data of Icosabutate from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Icosabutate in NASH.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Icosabutate?
• What is the clinical trial status of the study related to Icosabutate in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Icosabutate development?
• What are the key designations that have been granted to Icosabutate for NASH?
• What is the forecasted market scenario of Icosabutate for NASH?
• What are the forecasted sales of Icosabutate in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Icosabutate for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

This product will be delivered within 2 business days.